Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC

被引：0
|
作者：
Lamberti, G. [1 ]
Ricciuti, B. [1 ]
Alessi, J. V. [1 ]
Barrichello, A. P. C. [1 ]
Pecci, F. [1 ]
Vaz, V. R. [1 ]
Sholl, L. M. [2 ]
Awad, M. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
KRAS G12C; KRAS inhibitors; Predictive factors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.09
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [31] Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
    Stites, Edward C.
    Shaw, Andrey S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (05): : 342 - 351
  • [32] Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance
    Patel, Hetika Vora
    Smith, Alison
    Chan, Stacia
    Kessler, Linda
    Burrows, Francis
    Malik, Shivani
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Using the ResCu system for preclinical testing of KRAS G12C inhibitors
    Ruiz, Victor M.
    Hill, Lindsay
    Gadde, Manasa
    Bulow, Christopher
    Morri, Maurizio
    Goldner, Nicholas
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [34] Creating actionable neoantigens by design with KRAS(G12C) covalent inhibitors
    Maso, Lorenzo
    Hattori, Takamitsu
    Araki, Kiyomi
    Koide, Akiko
    Rajak, Epsa
    Hayman, James
    Akkapeddi, Padma
    Bang, Injin
    Neel, Benjamin G.
    Koide, Shohei
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [35] Novel natural inhibitors targeting KRAS G12C by computational study
    Jiang, Yuting
    Chen, Wanting
    Wang, Xinhui
    Zhou, Baolin
    Xie, Haoqun
    Hou, Yuanyuan
    Guo, Zhen
    Yu, Bo
    Zhong, Sheng
    Su, Xing
    ANTI-CANCER DRUGS, 2022, 33 (09) : 779 - 788
  • [36] Resistance looms for KRAS G12C inhibitors and rational tackling strategies
    Zhang, Junmin
    Zhang, Juanhong
    Liu, Qing
    Fan, Xing-Xing
    Leung, Elaine Lai-Han
    Yao, Xiao-Jun
    Liu, Liang
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [37] Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
    Finn, Stephen P.
    Addeo, Alfredo
    Dafni, Urania
    Thunnissen, Erik
    Bubendorf, Lukas
    Madsen, Line Bille
    Biernat, Wojciech
    Verbeken, Eric
    Hernandez-Losa, Javier
    Marchetti, Antonio
    Cheney, Richard
    Warth, Arne
    Speel, Ernst-Jan M.
    Quinn, Anne Marie
    Monkhorst, Kim
    Jantus-Lewintre, Eloisa
    Tischler, Verena
    Marti, Nesa
    Dimopoulou, Georgia
    Molina-Vila, Miguel A.
    Kammler, Roswitha
    Kerr, Keith M.
    Peters, Solange
    Stahel, Rolf A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 990 - 1002
  • [38] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. Prasad
    Prasad, A.
    Jantus-Lewintre, E.
    Ito, M.
    Cardona, A. F.
    Arrieta, O.
    Cao, P.
    Cai, X.
    Xing, B.
    Pedraz-Valdunciel, C.
    Dantes, Z.
    Sullivan, I.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
  • [39] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Fukui, Sarina
    Sawada, Ryo
    Tachibana, Yusuke
    Matsui, Yohei
    Nakamura, Ryota
    Ishida, Masaki
    Kawachi, Hayato
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Furuya, Naoki
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Nishioka, Naoya
    Horinaka, Mano
    Sakai, Toshiyuki
    Uehara, Hisanori
    Yano, Seiji
    Son, Bo-Kyung
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER LETTERS, 2024, 587
  • [40] Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
    Cao, Hang
    Ma, Zelin
    Huang, Qingyuan
    Han, Han
    Li, Yuan
    Zhang, Yang
    Chen, Haiquan
    EUROPEAN JOURNAL OF CANCER, 2024, 202
12345